Board/Management Information • May 24, 2013
Board/Management Information
Open in ViewerOpens in native device viewer
Lund, Sweden - May 24, 2013 - BioInvent International AB (STO: BINV) announces today that the Company's Board of Directors has appointed Michael Oredsson as new President and CEO. He will take office within six months.
Michael Oredsson has a degree in International Business Administration and has for many years held senior executive positions in the pharmaceutical and biotech industry. He is currently the CEO of Probi AB and has held his earlier executive positions at, among others, Pharmacia Corporation.
BioInvent's chairman Björn O. Nilsson says in a comment "We are very pleased to have been able to recruit a new CEO with a broad and international experience from different parts of the life science industry. We are confident that Michael's expertise and experience of licenses, contracts and commercial solutions and collaborations will be of great importance for our new strategic direction, which include increased focus on developing existing and new alliances with partners based on our technology platform and project portfolio."
"BioInvent is a very interesting company with broad knowledge, strong technologies and numerous partnerships in the field of antibody therapeutics. The company's new strategy provides exciting opportunities and I look forward to leading this work, "says Michael Oredsson.
-- END --
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.
The company's competitive position is underpinned by n-CoDeR® , a proprietary antibody development platform. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.
Björn O. Nilsson Cristina Glad Chairman of the board Acting President and CEO Mobile: +46 (0)70 218 15 00 Phone: +46 (0)46 286 85 51
Mobile: +46 (0)708 16 85 70 E-mail: [email protected] The Trout Group Christine Yang Vice President Phone: +1 646 378 2929 E-mail: [email protected]
Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 [email protected] www.bioinvent.com
Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 8.45 a.m. CET, on 24 May 2013.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.